Get the Daily Brief
Latest Biotech News
CrisprBits bags $3m – expands CRISPR diagnostics and R&D
Indian startup CrisprBits raised $3 million in a pre‑Series A round led by Spectrum Impact to expand CRISPR‑based diagnostics, gene‑editing R&D and sustainable biotech initiatives. The company...
Aspen Neuroscience Raises $115M Series C to Scale Parkinson’s iPSC Therapy
Aspen Neuroscience closed a $115 million Series C to advance its autologous iPSC-derived cell therapy ANPD001 and expand manufacturing. The company said the financing will accelerate clinical...
CrisprBits Secures $3M Pre‑Series A to Expand CRISPR Diagnostics
Indian startup CrisprBits closed a US$3 million Pre-Series A round led by Spectrum Impact to accelerate development of CRISPR-based diagnostics and R&D capabilities. The funding will support...
CSPC Cleared to Start Clinical Trials of JMT‑206 for Obesity in China
China’s NMPA granted clinical trial clearance for CSPC Pharmaceutical’s JMT-206 for weight management in obese or overweight patients with at least one comorbidity. The clearance allows CSPC to...
SK Biopharma Licenses WT‑7695 Radiopharmaceutical From WARF
SK Biopharmaceuticals signed an exclusive worldwide license with the Wisconsin Alumni Research Foundation to advance WT-7695, a preclinical radiopharmaceutical developed with the University of...
Kedrion Wins EMA Orphan Designation for Aceruloplasminemia Therapy
Kedrion SpA received European orphan drug designation from the EMA for its plasma-derived investigational therapy targeting congenital aceruloplasminemia. The designation supports Kedrion’s plans...
Talquetamab Outperforms Physician Choice in Relapsed/Refractory Myeloma Study
A recent comparative study reported talquetamab demonstrated superior efficacy compared with physician’s choice therapies in patients with relapsed multiple myeloma. The analysis, published in...
VT‑3989 TEAD Inhibitor Shows Preclinical Activity in NF2‑Deficient Tumors
Vivace Therapeutics presented preclinical data showing VT-3989, a TEAD inhibitor, elicited tumor growth inhibition in in vitro and in vivo models of aggressive NF2-deficient meningioma. VT-3989 is...
TNG‑456, a Next‑Gen PRMT5 Inhibitor, Shows Brain‑Active Antitumor Efficacy
Tango Therapeutics disclosed preclinical efficacy of TNG-456, a selective MTA-cooperative PRMT5 inhibitor, demonstrating antitumor activity in glioma and brain-metastatic tumor models. The program...
mRNA‑Engineered Allogeneic Cells and Off‑the‑Shelf mRNA Vaccines Advance Immuno‑oncology
Researchers reported two separate advances: an mRNA engineering approach that enhances allogeneic mesenchymal stem cells to create an off‑the‑shelf cell therapy dubbed DC-25, and an off‑the‑shelf...
New Small‑Molecule and Immune Targets Disclosed — STAT6 and cGAS Inhibitors
Two disclosures revealed new small-molecule inhibitor programs from established organizations: Kymera Therapeutics reported discovery of STAT6 inhibitors aimed at oncology and inflammatory...
Aspen raises $115m: scales personalized Parkinson’s cell therapy
Aspen Neuroscience closed a $115 million Series C to advance ANPD001, its autologous iPSC-derived cell therapy for Parkinson’s disease and to scale manufacturing, clinical operations and pipeline...
FDA’s plausible mechanism pathway...rare-disease approvals debated
US regulatory officials published a 'plausible mechanism pathway' framework in The New England Journal of Medicine proposing an expedited approval route for bespoke medicines for ultra-rare...
U.K. budget boosts venture funding – lab costs rise for biotechs
The U.K. budget introduced measures to widen venture and share‑option flexibility aimed at supporting biotech fundraising, but simultaneously raised business rates that could increase operating...
CrisprBits bags $3m...investors push maturity to cross valley of death
Indian CRISPR diagnostics startup CrisprBits raised US$3 million in a Pre-Series A round led by Spectrum Impact to expand CRISPR-based diagnostics and R&D capabilities. The funding aims to...
Allogeneic cell therapies advance: iNKT cells and mRNA‑enhanced MSCs
A phase 1 trial tested allogeneic iPSC-derived invariant natural killer T (iNKT) cells in recurrent head and neck cancer, marking progress for off-the-shelf engineered immune cells. The study...
China clears JMT-206...GLP-1 drugs still pose unanswered safety and efficacy questions
CSPC gained China NMPA clearance to begin clinical trials of JMT-206 for weight management in people with obesity or overweight with comorbidities, moving a domestic candidate into clinical...
Senescent cell immunization: two reports propose tumor-targeting vaccine strategy
Ichim et al. published work in the Journal of Translational Medicine describing 'senescent cell immunization' as a novel approach to target solid tumors by directing immune responses against...
Mechanisms meet therapeutics: NEK7 biology and CAR-macrophages attack liver fibrosis
Two independent preclinical advances target liver fibrosis from complementary angles. A CAR‑macrophage therapy reduced fibrosis in mouse models, demonstrating that engineered macrophages can be...
Next‑gen oncology inhibitors: PRMT5 and TEAD programs show preclinical traction
Tango Therapeutics reported preclinical efficacy for TNG‑456, a selective, MTA‑cooperative PRMT5 inhibitor showing antitumor activity in glioma and metastasis-prone tumors. The compound targets...